Loading...
XSTO
ERMA
Market cap19mUSD
Dec 05, Last price  
2.48SEK
1D
6.90%
1Q
-0.80%
Jan 2017
-71.83%
IPO
-67.07%
Name

Enorama Pharma AB

Chart & Performance

D1W1MN
XSTO:ERMA chart
P/E
P/S
11.73
EPS
Div Yield, %
Shrs. gr., 5y
51.22%
Rev. gr., 5y
15.68%
Revenues
16m
+1,061.12%
1,383,2431,993,7783,991,2041,572,8905,256,0117,610,7172,146,00011,036,0006,847,0001,358,00015,768,000
Net income
-44m
L-1.81%
-20,000-656,000-7,836,114-8,755,754-16,339,339-24,721,571-23,901,000-28,544,000-41,780,000-44,613,000-43,806,000
CFO
-36m
L-13.66%
307,000480,000-6,114,487-6,666,545-13,360,169-26,563,507-22,998,000-30,164,000-32,958,000-41,349,000-35,702,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.
IPO date
Jun 10, 2016
Employees
9
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT